<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="UTF-8">
  <meta http-equiv="X-UA-Compatible" content="IE=edge">
  <meta name="viewport" content="width=device-width, initial-scale=1.0">
  <link rel="shortcut icon" href="../images/favicon.png" type="image/x-icon">
  <title>Gestational Trophoblastic Diseases (GTDs)</title>
  <link href="https://cdn.jsdelivr.net/npm/remixicon@2.5.0/fonts/remixicon.css" rel="stylesheet">
  <link rel="stylesheet" href="../style.css">
  <link rel="stylesheet" href="../notes.css">
</head>
<body>
  <input type="checkbox" id="main-navigation-toggle" class="btn btn--close" title="Toggle main navigation" />
  <label for="main-navigation-toggle">
    <span></span>
  </label>
  
  <a href="../index.html">
   <div class="home-navigation">
      mtr<span class="logo-dot">.</span>
    </div>
  </a>


    <nav id="main-navigation" class="nav-main">
    <ul class="menu">
      <li class="menu__item">
        <a class="menu__link" href="../index.html">Home</a>
      </li>

      <li class="menu__item">
        <a class="menu__link" href="../about-temp2.html">About</a>
      </li>
    </ul>
  </nav>
  
      <!-- Toggle switch for dark mode -->
      <div class="dark-mode-toggle">
        <label class="switch-toggle">
            <input type="checkbox" id="dark-mode-toggle-checkbox">
            <span class="toggle-slider"></span>
        </label>
      </div>

      <!-- Progress Bar  -->
      <div id="progress-container">
        <div id="progress-bar"></div>
    </div>
      
<!-- SIDEBAR -->
<div id="sidebar" class="sidebar">
  <button id="closeSidebarBtn" class="btn toggle-btn close-btn">Close</button>
  <ul class="sidebar-menu toggle-menu">
    <!-- Add the list of topics dynamically using JavaScript -->
  </ul>
</div>

<!-- Toggle button to open the sidebar -->
<button id="toggleSidebarBtn" class="btn toggle-btn">&#9776;</button>

<!-- END OF SIDEBAR -->

  <main class="page-container">
    <div class="contribute-cta">
      <p>Help make this betterüíú</p>
      <span><a href="../contribute.html">Contribute here</a> </span>
    </div>

    <h1>Gestational Trophoblastic Diseases (GTDs)</h1>
  
    <!-- <div class="author-flex">
      <div class="author-img">
        <img  src="/contributors/vt1.jpeg" alt="">
      </div>
      <div>
        <h2 class="name">Compiled by Victortayo</h2>
        <p class="updated">last updated, Nov 2022</p>
      </div>
    </div> -->

    <article class="notes">
      <a id='top'></a>
  <article>

        <!-- LEARNING OBJECTIVES CONTAINER  -->
            <div class="custom-card" id="custom-card-1">
              <div class="icon"><img src="../images/icons/light-bulb.png" alt="Icon" class="icon"></div>
              <div class="title"> 
                <h2>What You Will Learn</h2>
              </div>
              <div class="line">
                <p>After reading this note, you should be able to...</p>
              </div>
              <div class="content">
                <ul>
                  <li><i>This content is not available yet.</i></li>
              </ul>
              </div>
              <div class="read-more" onclick="toggleContent('custom-card-1')">Read More üç™</div>
            </div>
          
        <!-- END OF LEARNING OBJECTIVES CONTAINER  -->
      
      
        <!-- SHOW AND HIDE OUTLINE CONTAINER  -->
          <div class="outline2">
      
            <input type="radio" name="control-2" id="show-2">
            <label for="show-2">üêµ&nbsp; &nbsp;Show Outline</label>
            <input type="radio" name="control-2" id="hide-2">
            <label for="hide-2">üôà&nbsp; &nbsp; Hide Outline</label>
            <div class="contents">
              <div class="icon-box">
                <!-- Replace 'path/to/your/icon.png' with the actual path to your PNG icon -->
                <img src="../images/icons/book.png" alt="Icon" class="icon">
              </div>
              <div id="tableOfContents">
                  <ol id="tocList"></ol>
              </div>
            </div>
           <div>
      
      <!-- END OF SHOW AND HIDE OUTLINE CONTAINER  -->

      <br>

      <section id='header-1'>
        <header>
          <h2>
            <a aria-hidden='true' href='#header-1'>Introduction</a>
          </h2>
        </header>
        <div class='body'>
            <p>Gestational trophoblastic disease (GTD) is a spectrum of tumors that develop from an aberrant fertilization event and hence arise from fetal tissue within the maternal host, this makes them unique.</p>
            <p>They arise from over-production of chorionic tissue (which usually should develop into the placenta)</p>
            <p>GTD represents a spectrum of premalignant and malignant diseases</p>
            <p>They have varying propensities for local invasion and metastasis. </p>
        </div>

      </section>

      <section id='header-2'>
        <header>
          <h2>
            <a aria-hidden='true' href='#header-2'>Origin/Biology</a>
          </h2>
        </header>
        <div class='body'>
            <p>The trophoblast is extraembryonic but fetal in origin.</p>
            <p>The trophoblastic cells are the epithelial component of the placenta and are divided into three cytologically and functionally distinct populations. </p>
            <ol>
                <li>Cytotrophoblastic(CT) cells </li>
                <li>Syncytiotrophoblastic(ST) cells </li>
                <li>Intermediate trophoblastic (IT) cells</li>
            </ol>

            <h4><span class="special-text-4b">Cytotrophoblast </span></h4>
            <ul>
                <li>The cytotrophoblast is a stem cell with high mitotic activity but without hormonal synthesis</li>
            </ul>
            <h4><span class="special-text-4b">Intermediate trophoblast</span></h4>
            <ul>
                <li>The intermediate trophoblast has features of the other two components and is responsible for endometrial invasion and implantation</li>
            </ul>
            <h4><span class="special-text-4b">Syncytiotrophoblast</span></h4>
            <ul>
                <li>The syncytiotrophoblast constitutes the villous trophoblast. It has low mitotic activity. The syncytiotrophoblast is responsible for the synthesis of the beta-hCG.</li>
            </ul>


            <p>Trophoblastic cells express a number of proteins.</p>
            <ul>
                <li>B-hCG (human Chorionic Gonadotrophin)</li>
                <li>hPL (human Placental lactogen)</li>
                <li>Placental alkaline phosphatase (PLAP)</li>
                <li>Inhibin-a</li>
            </ul>
        </div>
      </section>

      <section id='header-3'>
        <header>
          <h2>
            <a aria-hidden='true' href='#header-3'>Classification of GTDs</a>
          </h2>
        </header>
        <div class='body'>
            <ol>
                <li>Benign Forms (90%)</li>
                <ul>
                    <li>Complete hydatidiform mole (CHM)</li>
                    <li>Partial hydatidiform mole (PHM)</li>
                </ul>
                <li>Malignant Forms (10%)</li>
                <ul>
                    <li>Invasive mole</li>
                    <li>Choriocarcinoma</li>
                    <li>Placental site trophoblastic tumor (PSTT)</li>
                    <li>Epithelioid trophoblastic tumor</li>
                </ul>
            </ol>

            <div class="tips-card">
                <p class="tips-card-subtitle">note</p>
                <h4 class="tips-card-title">
                  Points to note
                </h4>
                <p class="tips-card-content">
                  <ul>
                    <li>Complete molar pregnancies are generally diploid, and all chromosomes are of paternal origin.</li>
                    <li>Complete moles are being diagnosed earlier in pregnancy and less frequently present with the classic signs and symptoms.</li>
                    <li>Partial molar pregnancies are triploid, and the extra set of chromosomes is paternal</li>
                    <li>Although malignant gestational trophoblastic diseases most commonly follow a molar pregnancy, they can occur after any gestational event, including induced or spontaneous abortion, ectopic pregnancy, or term pregnancy.</li>
                  </ul>
                    
                </p>
              </div>

              <section id='heading-3-1'>
                <header>
                  <h3>
                    <a aria-hidden href='#heading-3-1'>Benign (Hydatidiform mole)</a>
                  </h3>
                </header>
                <div class='body'>
                    <p>Can be complete or partial mole</p>

                    <section id='heading-3-1-1'>
                        <header>
                          <h4>
                
                            <a aria-hidden href='#heading-3-1-1'>Epidermiology</a>
                          </h4>
                        </header>
                        <div class='body'>
                            <p>Hydatidiform mole is the most common form of gestational trophoblastic disease and is benign in nature.</p>
                            <p>2% of all miscarriages.</p>
                            <p>Its incidence varies worldwide. </p>
                            <ul>
                                <li>1 in 1500 deliveries in the United States</li>
                                <li>1 in 400 pregnancy in Nigeria</li>
                                <li>1 in 200 pregnancy in Indonesia</li>
                                <li>1 in 125 deliveries in Mexico and Taiwan </li>
                            </ul>
                
                        </div>
                    </section>

                    <section id='heading-3-1-2'>
                        <header>
                          <h4>
                
                            <a aria-hidden href='#heading-3-1-2'>Risk Factors</a>
                          </h4>
                        </header>
                        <div class='body'>
                            <ul>
                                <li>Race (blacks/Asians). In many Asian countries, the rates may be as high as 8‚Äì10 cases per 1,000 population.</li>
                                <li>Age <20yrs; >40yrs. The risk of development of H. mole in women older than 40 years is about five times more than that in younger women.</li>
                                <li>Parity- Nulliparity.</li>
                                <li>Low SES (Socioeconomic Status).</li>
                                <li>Deficiency of protein, folic acid and carotene.</li>
                                <li>Blood group- O highest; A least.</li>
                                <li>Previous history of molar pregnancy.</li>
                                <li>Partial mole is reported to be associated with the use of oral contraceptives, history of irregular menstruation and not with dietary factors</li>
                            </ul>
                
                        </div>
                    </section>

                    <section id='heading-3-1-3'>
                        <header>
                          <h4>
                
                            <a aria-hidden href='#heading-3-1-3'>Clinical Presentation</a>
                          </h4>
                        </header>
                        <div class='body'>
                            <p>Abnormal vaginal bleeding (75%) +/- passage of vesicles</p>
                            <p>Initially, the symptoms may be suggestive of early pregnancy; however the uterus is often larger than the period of gestation. </p>
                            <p>Absent fetal movements and heart tones</p>
                            <p>Passage of grape-like tissue is strongly suggestive of the diagnosis of H. mole.</p>
                            <p>Excessive nausea and vomiting.</p>
                            <p>Symptoms suggestive of hyperthyroidism (tachycardia, restlessness, nervousness, heat intolerance, unexplained weight loss, diarrhea, tremors in hands, etc.)</p>
                            <p>Excessive nausea and vomiting in cases of H mole may be related to high serum levels of Œ≤ hCG. Hyperemesis may commonly occur.</p>
                            <p> Commonly the nausea and vomiting may be severe enough to require hospitalization.</p>
                            <p>Early-onset pre-eclampsia</p>
                            <p>Anaemia</p>
                            <p>Thrombo-embolism</p>
                            <p>Large theca lutein cysts</p>
                            <p>Metastasis to the lungs (in cases of malignant moles) may result in symptoms like dyspnea, cough, hemoptysis, chest pain, etc.</p>
                
                            <figure>
                                <img src="../figures/gtd (1).png" alt="">
                                <figcaption> Clinical and Cytogenetic Comparison of Hydatidiform Moles</figcaption>
                               </figure>
                        </div>
                    </section>

                    <section id='heading-3-1-4'>
                        <header>
                          <h4>
                
                            <a aria-hidden href='#heading-3-1-4'>Investigations</a>
                          </h4>
                        </header>
                        <div class='body'>
                            <p>Ultrasound Scan</p>
                            <ul>
                                <li>USS in the first trimester may not be reliable. The typical ‚Äòsnowstorm‚Äô appearance occurs mainly in the second trimester, showing a heterogenous mass with no fetal development.</li>
                                <figure>
                                    <img src="../figures/gtd (3).jpg" alt="">
                                    <figcaption> </figcaption>
                                   </figure>
                                <li>Large ovarian cysts, called theca-lutein cysts can also be seen. They are often bilateral</li>
                            </ul>
                            <p>Histology</p>
                            <ul>
                                <li>Definitive diagnosis is made by histological examination of the product of conception.</li>
                                <li>Different forms of GTD have distinctive morphological features, depending on which tissues they are derived from.</li>
                            </ul>
                            <p>Serum HCG</p>
                            <p>Complete blood picture</p>
                            <p>Renal and Liver function tests</p>
                            <p>Chest X-ray</p>
                            <p>Thyroid function test</p>
                
                        </div>
                    </section>

                    <section id='heading-3-1-5'>
                        <header>
                          <h4>
                
                            <a aria-hidden href='#heading-3-1-5'>Treatment</a>
                          </h4>
                        </header>
                        <div class='body'>
                            <h4><span class="special-text-4">Supportive (Medical)</span></h4>
                            <p>Stabilize patient.</p>
                            <ul>
                                <li>Transfuse for anemia.</li>
                                <li>Correct any coagulopathy.</li>
                                <li>Treat hypertention.</li>
                            </ul>
                            <p>Watch and prepare for treatment of thyroid storm.</p>
                
                            <h4><span class="special-text-4">Definitive (Surgical)</span></h4>
                            <ul>
                                <li>Suction curettage with high pressure pump is the method of choice.</li>
                                <li>Intravenous oxytocin should be started at the commencement of Suction curettage.</li>
                                <li>All Rh-negative patients should receive Anti-D immune globulin.</li>
                                <li>Send Products evacuated for Histology.</li>
                            </ul>

                            <div class="tips-card">
                                <p class="tips-card-subtitle">note</p>
                                <h4 class="tips-card-title">
                                  Other treatment modalities?
                                </h4>
                                <p class="tips-card-content">
                                  <ul>
                                    <li>Hysterectomy remains an option for good surgical candidates not desirous of future pregnancy and for older women; this procedure may reduce the risk of subsequent malignancy</li>
                                    <li>Hysterotomy is not a method of choice in typical cases.</li>
                                    <li>Medical induction is not an acceptable method.</li>
                                  </ul>
                                    
                                </p>
                              </div>
        
                        </div>
                    </section>

                    <section id='heading-3-1-6'>
                        <header>
                          <h4>
                
                            <a aria-hidden href='#heading-3-1-6'>Post Molar Pregnancy Surveillance</a>
                          </h4>
                        </header>
                        <div class='body'>
                            <h4><span class="special-text-4b">1. Serial Œ≤‚ÄìhCG.</span></h4>
                            <ul>
                                <li>Beginning within 48 hours after evacuation and then at weekly intervals until serum -hCG declines to nondetectable levels on three successive assays.</li>
                                <li>(In benign disease, human chorionic gonadotropin concentrations spontaneously return to normal by eight weeks following evacuation of molar pregnancy)</li>
                                <li>Monthly for at least 1 year.</li>
                            </ul>

                            <h4><span class="special-text-4b">2. Gynaecologic examinations. </span></h4>
                            <ul>
                                <li>Uterine size and presence of adnexal masses (theca lutein cysts) and a careful search of the vulva, vagina, urethra, and cervix should be made for evidence of genital tract metastases.</li>
                                <li>Commence one week after evacuation.</li>
                                <li>Repeated at 4-week intervals for one year.</li>
                            </ul>

                            <h4><span class="special-text-4b">3. Chest radiography. </span></h4>
                            <ul>
                                <li>Pre - evacuation Chest X-ray.</li>
                                <li>Then at 3-month intervals for one year</li>
                            </ul>

                            <h4><span class="special-text-4b">4. Contraception for one year</span></h4>
                            <p>(Aim of 1, 2, 3, above is to determine if there is need for Chemotherapy)</p>

                
                        </div>
                    </section>

                    <section id='heading-3-1-7'>
                        <header>
                          <h4>
                
                            <a aria-hidden href='#heading-3-1-7'>Prognosis</a>
                          </h4>
                        </header>
                        <div class='body'>
                            <p>Excellent following evacuation.</p>
                            <p>However 10‚Äì15% of patients develop malignant form of the disease.</p>
                
                        </div>
                    </section>

                    <section id='heading-3-1-8'>
                        <header>
                          <h4>
                
                            <a aria-hidden href='#heading-3-1-8'>Indications for Chemotherapy</a>
                          </h4>
                        </header>
                        <div class='body'>
                            <p>When the plateau of HCG lasts for four measurements over a period of 3 weeks or longer (day1, 7, 14, 21)</p>
                            <p>Serum level of hCG >20,000 IU/l more than 4 weeks after evacuation </p>
                            <p>Raised hCG level six months after evacuation</p>
                            <p>When there is a rise of hCG of three weekly consecutive measurements or longer over a period of 2 weeks or more (days 1, 7, 14)</p>
                            <p>Histological evidence of Choriocarcinoma</p>
                            <p>The presence of metastases in brain, liver, gastrointestinal tract, lungs, vulvar or vaginal walls.</p>
                
                            <figure>
                                <img src="../figures/gtd (2).jpeg" alt="">
                                <figcaption> </figcaption>
                               </figure>
                        </div>
                    </section>
                </div>
              </section>

              <section id='heading-3-2'>
                <header>
                  <h3>
                    <a aria-hidden href='#heading-3-2'>Malignant GTDs</a>
                  </h3>
                </header>
                <div class='body'>
                   <ul>
                    <li>Invasive mole</li>
                    <li>Choriocarcinoma</li>
                    <li>Placenta site trophoblastic tumor</li>
                   </ul>

                   <h4><span class="special-text-4">Invasive Mole</span></h4>
                   <ul>
                    <li>10 - 15% of patients who have undergone evacuation of a molar pregnancy.</li>
                    <li>Mole that penetrates or even perforates the uterine wall with invasion of the myometrium by Chorionic villi, accompanied by proliferation of both cytotrophoblast and syncytiotrophoblast.</li>
                    <li>Embolize to distant sites, such as lungs and brain, but do not grow in these organs as true metastases.</li>
                   </ul>
                   <h4><span class="special-text-4">Choriocarcinoma</span></h4>
                   <ul>
                    <li>2‚Äì5% of all cases of gestational trophoblastic neoplasia.</li>
                    <li>Derived from a previously normal or abnormal pregnancy </li>
                    <li>Malignant tumor derived from normal or abnormal placental tissue</li>
                    <li>Choriocarcinoma is a pure epithelial tumor composed of syncytiotrophoblastic and cytotrophoblastic cells.</li>
                    <li>Histologic evaluation of the tumor discloses sheets or foci of trophoblasts on a background of hemorrhage and necrosis, but no villi</li>
                   </ul>
                   <h4><span class="special-text-4"> Placenta Site Trophoblastic Tumor</span></h4>
                   <ul>
                    <li>PSTT is a rare variant of gestational trophoblastic tumor.</li>
                    <li>Compose less than 2% of gestational trophoblastic neoplasms - 75% of cases follow normal pregnancy,   5% of cases have preceding molar pregnancy.</li>
                    <li>Neoplastic proliferation of extravillous trophoblastic (intermediate trophoblast).</li>
                    <li>Syncytiotrophoblastic cells are generally absent from this tumor, minimal amounts of hCG are released in relation to the tumor burden. However, human placental lactogen is secreted.</li>
                   </ul>

                   <section id='heading-3-2-2'>
                    <header>
                      <h4>
            
                        <a aria-hidden href='#heading-3-2-2'>Pathology</a>
                      </h4>
                    </header>
                    <div class='body'>
                        <p>Invasive mole</p>
                        <ul>
                            <li> Villi penetrate deeply: Myometrium, blood vessels</li>
                        </ul>
                        <p>Choriocarcinoma</p>
                        <ul>
                            <li>Tumor mass is dark-red, hemorrhagic, and nodular</li>
                        </ul>
                        <p>Placenta site trophoblastic tumour</p>
                        <ul>
                            <li>Deep uterine penetration, myometrial mass may be well localized or ill defined. Hemorrhage is not as conspicuous as in invasive mole or as in choriocarcinoma. </li>
                        </ul>
            
                    </div>
                   </section>

                   <section id='heading-3-2-3'>
                    <header>
                      <h4>
            
                        <a aria-hidden href='#heading-3-2-3'>Diagnosis </a>
                      </h4>
                    </header>
                    <div class='body'>
                        <p>Findings at post evacuation surveillance, OR</p>
                        <p>Presenting symptoms & signs of metastases - </p>
                        <ul>
                            <li>Sub-urethral nodule in the vagina</li>
                            <li>Hemoptysis    </li>
                            <li>Abdominal pain/tenderness </li>
                            <li>Hematuria</li>
                            <li>Seizures</li>
                            <li>Coma </li>
                        </ul>
            
                    </div>
                   </section>

                   <section id='heading-3-2-4'>
                    <header>
                      <h4>
            
                        <a aria-hidden href='#heading-3-2-4'>Investigations</a>
                      </h4>
                    </header>
                    <div class='body'>
                        <p>Full blood count.</p>
                        <p>Renal and liver function tests.</p>
                        <p>Serum HCG.</p>
                        <p>Chest X-ray.</p>
                        <p>Ultrasound of pelvis and liver.</p>
                        <p>Brain MRI or CT Scanning</p>
                        <p>CT or MRI of other parts of body as indicated</p>
            
                    </div>
                   </section>

                   <section id='heading-3-2-5'>
                    <header>
                      <h4>
            
                        <a aria-hidden href='#heading-3-2-5'>FIGO Anatomic Staging of GTN</a>
                      </h4>
                    </header>
                    <div class='body'>
                        <p>Stage 1: Disease confined to the uterus</p>
                        <p>Stage 2: GTT extends outside the uterus but is limited to genital structures (vagina, broad ligament, adnexa)</p>
                        <p>Stage 3: GTT extends to the lungs with or without genital tract involvement.</p>
                        <p>Stage 4: All other metastatic sites </p>
                        <p>The goal of the revised FIGO staging is to improve the assessment and clinical management of patients and to unify staging to allow for international comparisons in treatment success.</p>
            
                    </div>
                   </section>

                   <section id='heading-3-2-6'>
                    <header>
                      <h4>
            
                        <a aria-hidden href='#heading-3-2-6'>Classification of Gestational Trophoblastic Diseases for Treatment and Prognosis.</a>
                      </h4>
                    </header>
                    <div class='body'>
                        <ul>
                            <li>Non metastatic disease (stage I).</li>
                            <li>Low-risk metastatic - stages II and III (score < 7).</li>
                            <li>High-risk metastatic - stage IV (score ‚â• 7)</li>
                        </ul>
                        <p> Risk factor score based on the WHO prognostic scoring system.</p>
                        
                        <figure>
                            <img src="../figures/gtd (4).png" alt="">
                            <figcaption> </figcaption>
                           </figure>
                           
                    </div>
                   </section>

                   <section id='heading-3-2-7'>
                    <header>
                      <h4>
            
                        <a aria-hidden href='#heading-3-2-7'>Treatment</a>
                      </h4>
                    </header>
                    <div class='body'>
                        <h4><span class="special-text-4">Low-risk metastatic disease</span></h4>
                           <ul>
                            <li>Single-agent Chemotherapy with methotrexate or Actinomycin D.</li>
                           </ul>
                           <h4><span class="special-text-4">High-risk metastatic disease</span></h4>
                           <p>Multiagent chemotherapy with or without adjuvant surgery or radiation therapy</p>
                           <p>High-risk metastatic disease multiagent Chemotherapy could be: </p>
                           <p>MAC - Methotrexate + Actinomycin D + Cyclophosphomide, OR</p>
                           <p>EMA-CO: Etoposide + Methotrexate + Actinomycin D ‚Äì Cyclophosphomide + Oncovin.</p>
                           <p>Adjuvant surgical procedures that may be needed in hemorrhage or refractory nodule not responsive to Chemotherapy in High risk disease include;</p>
                           <ul>
                            <li>Hysterectomy</li>
                            <li>Hepatic artery embolization</li>
                            <li>Craniotomy</li>
                            <li>Thoracotomy</li>
                           </ul>
            

                           <h4><span class="special-text-4">Treatment of PSTT </span></h4>
                           <ul>
                            <li>It is generally resistant to chemotherapy </li>
                            <li>Hysterectomy is the recommended route of treatment</li>
                            <li>Partial uterine resection involving the tumor is possible if the patient desires future fertility. </li>
                            <li>Chemotherapy is indicated in cases of metastatic disease.</li>
                           </ul>

                           <h4><span class="special-text-4">Follow-up after treatment for GTT.</span></h4>
                           <ul>
                            <li>Serum quantitative hCG levels should be obtained at 1-month intervals for 12 months.</li>
                            <li>Contraception should be maintained during treatment and for 1 year after completion of chemotherapy.</li>
                            <li>Pelvic ultrasound is recommended in the first trimester of a subsequent pregnancy to confirm a normal gestation.</li>
                            <li>Serum quantitative hCG level should be determined 6 weeks after any pregnancy.</li>
                           </ul>
                    </div>
                  </section>

                  <section id='heading-3-2-8'>
                    <header>
                      <h4>
            
                        <a aria-hidden href='#heading-3-2-8'>Prognosis</a>
                      </h4>
                    </header>
                    <div class='body'>
                        <h4><span class="special-text-4">Malignant non-metastatic disease.</span></h4>
                        <ul>
                            <li>Quite good, as almost all patients are cured.</li>
                            <li>90% of patients can preserve reproductive function.</li>
                        </ul>
                        <h4><span class="special-text-4">Metastatic disease</span></h4>
                        <ul>
                            <li>Best results are with EMACO chemotherapy and concurrent radiation as indicated.</li>
                            <li>About 75% - 85% of patients achieve remission with a 69% salvage rate.</li>
                        </ul>
            
                    </div>
                  </section>
                </div>
              </section>

        </div>
      </section>

      <section id='header-4'>
        <header>
          <h2>
            <a aria-hidden='true' href='#header-4'>Conclusion</a>
          </h2>
        </header>
        <div class='body'>
            <p>After achieving remission with chemotherapy, patients with gestational trophoblastic tumors can generally anticipate normal reproduction in the future.    </p>
        </div>
      </section>


      <hr style="margin: 3rem 0;">

      <!-- PRACTICE QUESTIONS CONTAINER -->

      <div class="custom-card" id="custom-card-2">
        <div class="icon"><img src="../images/icons/practice-questions.png" alt="Icon" class="icon"></div>
        <div class="title"> 
          <h2>Practice Questions</h2>
        </div>
        <div class="line">
          <p>Check how well you grasp the concepts by answering the following questions...</p>
        </div>
        <div class="content">
          <ol>
            <li><i>This content is not available yet.</i></li>
          </ol>
        </div>
        <div class="read-more" onclick="toggleContent('custom-card-2')">Read More üç™</div>
      </div>

      <!-- END OF PRACTICE QUESTIONS CONTAINER -->


      <!-- CONTACT- COMMENT AND CONTRIBUTORS CONTAINER -->
      <div class="contact">
        <div class="comment-container">
          <div class="comment-icon">
            <!-- Add your icon image here -->
            <img src="../images/icons/comment.png" alt="Comment Icon">
          </div>
          <div class="comment-text">
            <!-- Add your text here -->
            <p>Send your comments, corrections, explanations/clarifications and requests/suggestions </p>
          </div>
          <a href="https://docs.google.com/forms/d/e/1FAIpQLSdx2teDCmW6ivSeKLQg7zF_jy7Yfg_1Gqm84_UT0PQPATsNug/viewform?usp=sf_link" class="comment-button">
            here
            <!-- <img src="../images/icons/whatsapp.png" alt="Image Icon"> -->
          </a>
        </div>


      </div>

            <!-- END OF CONTACT- COMMENT AND CONTRIBUTORS CONTAINER -->
    </article>
   </article>
   <div style="height: 300px;"></div>
  </main>

  <footer>
    <div class="footer-container">
        <div>
          <p id="popup-trigger">disclaimer</p>

          <!-- The pop-up dive content -->
          <div id="popup" class="popup">
            <p>The contents on this ‚Äòwebsite‚Äô are for educational purposes only. The creators and operators of this website make no warranties, express or implied, regarding the accuracy, currency, or completeness of the information provided on the website. They shall not be held responsible for any errors or omissions, or for any actions taken based on the information provided on this website.</p>
            <button class="popup-close" onclick="closePopup()">Close</button>
          </div>    
          <p><a href="../about-temp2.html">about</a> </p>   
          <p><a href="../contribute.html">contribute</a> </p>
        </div>

        <div class="footer-beta">
          <p>thisisatestversion</p>
        </div>
    </div>
  </footer>
<!------------  SCROLL UP ----------->
<a href="#" class="scrollup" id="scroll-up"> 
  <i class="ri-arrow-up-fill scrollup__icon"></i>
</a>
<script src="../main.js"></script>
<script src="../modal.js"></script>
<script src="../notes-sidebar.js"></script>

<script>
  // Dynamically generate TOC from <h2> headings within <section> elements
    const tocList = document.getElementById('dynamic-toc');
  const sections = document.querySelectorAll('section');
  const tocButton = document.getElementById('toc-button');
  const tocPanel = document.getElementById('toc-panel');
  
  // Generate Table of Contents
  sections.forEach(section => {
      const headings = section.querySelectorAll('h2');
      headings.forEach(heading => {
          const headingAnchor = heading.querySelector('a');
          if (headingAnchor && headingAnchor.getAttribute('href')) {
              const tocItem = document.createElement('li');
              const link = document.createElement('a');
              link.textContent = headingAnchor.textContent || 'Untitled Section';
              link.href = headingAnchor.getAttribute('href');
              tocItem.appendChild(link);
              tocList.appendChild(tocItem);
          }
      });
  });
  
  // Hide TOC button initially
  tocButton.style.display = 'none';
  
  // Show/hide TOC button on scroll
  window.addEventListener('scroll', () => {
      // Show button after scrolling down 200 pixels
      if (window.scrollY > 200) {
          tocButton.style.display = 'block';
      } else {
          tocButton.style.display = 'none';
          tocPanel.classList.remove('expanded');
      }
  });
  
  // Toggle TOC panel
  tocButton.addEventListener('click', (event) => {
      event.stopPropagation(); // Prevent immediate closure
      tocPanel.classList.toggle('expanded');
  });
  
  // Close TOC panel when clicking outside
  document.addEventListener('click', (event) => {
      if (tocPanel.classList.contains('expanded') && 
          !tocPanel.contains(event.target) && 
          event.target !== tocButton) {
          tocPanel.classList.remove('expanded');
      }
  });
  
  
  </script>
  
</body>
</html>
 
